BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN PATIENTS WITH REFRACTORY/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) AND REFRACTORY/RECURRENT SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL):